A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors | MicrobiomeTrials← Back to trialsNCT05159388
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors
TERMINATEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2021-09-08Est. Completion: 2025-04-01
Enrollment target: 46 participants Locations- Carolina Bio Oncology, Huntersville, North Carolina, United States
- NEXT Oncology, San Antonio, Texas, United States
- Cabrini Oncology Research, Malvern, Victoria, Australia
- Chris O'Brian Lifehouse, Camperdown, Australia
- The Queen Elizabeth Hospital, Woodville South, Australia
- Institute Jules Bordet, Brussels, Belgium
- Universitair Ziekenhuis, Edegem, Belgium
- U.Z. Gent Medical Oncology, Ghent, Belgium
- Hospital Vall d'Hebron, Barcelona, Spain
- START, Madrid, Spain
- Hospital Universitario Gregorio, Madrid, Spain
Other microbiome trials you might be interested in
Solid CancerHaematological Malignancies
This is an open-label, single-centre, category 2 "Jardé Law" proof-of-concept study designed to demonstrate the feasibil…
Toulouse, FranceEst. completion May 19, 2027
Advanced/Metastatic Non-Small Cell Lung Cancer
This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metas…
Goodyear, United StatesEst. completion Jun 24, 2030
The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer.…
New York, United StatesEst. completion Jul 2027